Updates are available Correction dated 2026-05-09

Article History

Received: 26 December 2025

Accepted: 7 March 2026

First Online: 20 March 2026

Change Date: 4 May 2026

Change Type: Update

Change Details: "The original online version of this article was revised: In the original version of this manuscript, the antibiotic prophylaxis shown in the grey box in Table 2 was captured as normal text. This should be captured and presented in the same way as in the original table, as it reflects the correct timing of antibiotic administration in relation to vaccine administration, as specified in the text (“Prophylaxis with penicillin or amoxicillin from treatment start to 15 days after the second vaccine dose”).

Change Date: 9 May 2026

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10072-026-09058-5

Declarations

:

: The study has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Specific national laws was observed.

: LF received financial support from Alexion Pharmaceuticals, argenx, UCB, Dianthus, Johnson & Johnson and amgen. PEA received financial support from Alexion Pharmaceuticals, argenx, UCB. CA received funding for travel, meeting attendance and advisory board participation from argenx, Alexion, UCB and Johnson & Johnson. DMB received honoraria for Advisory board: Argenx, Alexion, Roche. Research support as PI for Roche and Alexion. Speaker’s Honoraria from Argenx, Alexion, UCB. VD has received public speaking honoraria and compensation for advisory boards and/or consultations fees from UCB, Argenx, Amgen, Alexion Pharmaceuticals, Dianthus, Roche. FH has received financial support from Abvie, Alexion Pharmaceuticals, Alnylam, Amgen, Angelini, Argenx, Alfa Sigma, Behring, Ipsen, Lusofarma, Merck, Roche, Takeda, UCB, and Johnson & Johnson. MI has received financial support from Alexion Pharmaceuticals, argenx, Regeneron and Johnson & Johnson. RI has received speaker honoraria from Alexion, Argenx, Johnson & Johnson, Merck, The Sumaira Foundation, and UCB, and has participated in advisory boards for Alexion, Amgen, Argenx, Dianthus Therapeutics, Johnson & Johnson, Merck, and UCB. RL received funding from MAYA IDEE SUD s.r.l.; ISS; QbGROUP s.r.l.; Symposium s.r.l.; Accademia Nazionale Di Medicina; AIM Italy s.r.l.; argenx; ARISTEA International s.r.l.; Clinical Learning s.r.l.; Takeda; UCB Pharma S.p.A.; first class s.r.l.; janssen-cilag S.p.A.; Amgen s.r.l.; Alfasigma S.p.A.; MATERIA PRIMA s.r.l. MMT has received financial support from Alexion Pharmaceuticals, argenx, UCB, Dianthus, Regeneron, Idorsia and Johnson & Johnson. LM has received honoraria for speaking, advisory boards, and compensation for congress participations from Sanofi, Roche, Biogen, Amicus Therapeutics, Alexion, Argenx, UCB, Johnson & Johnson, and Lupin, outside the submitted work. LM also received funding for fellowship from Biogen and Alexion. ReM received funding for Travel, Meeting attendance or Advisory Board participation from Alexion, Argenx, Biomarin, Catalyst, SANOFI, Regeneron and UCB. RoM has received financial support from Alexion, Johnson & Johnson, UCB, Merck. EP acknowledges payments or honoraria for lectures, presentations, speakers bureaus, or educational events from Biogen and Roche; support for attending meetings and/or travels from Roche, Biogen, and Alexion; payments for participation on Advisory Board from Alexion, Santhera, UCB Biopharma, and Sanofi. MP has nothing to disclose. CR has received financial support for advisory boards and sponsorship for congresses from Alexion, Argenx, Amgen, Johnson & Johnson, UCB Pharma. GA received conference honoraria, advisory board and travel grants from Kedrion, Alnylam, Alexion, Argenx, Takeda. AE received honoraria for scientific award jury member (Grifols), speaker (UCB) and advisory board participation (Dianthus).